ATE147387T1 - Perfluoro-hexamethyltetramin und synthetische phopholipide, verwendbar als synthetisches blut - Google Patents

Perfluoro-hexamethyltetramin und synthetische phopholipide, verwendbar als synthetisches blut

Info

Publication number
ATE147387T1
ATE147387T1 AT87307490T AT87307490T ATE147387T1 AT E147387 T1 ATE147387 T1 AT E147387T1 AT 87307490 T AT87307490 T AT 87307490T AT 87307490 T AT87307490 T AT 87307490T AT E147387 T1 ATE147387 T1 AT E147387T1
Authority
AT
Austria
Prior art keywords
synthetic
phopholipides
hexamethyltetramine
perfluoro
usable
Prior art date
Application number
AT87307490T
Other languages
English (en)
Inventor
Walter B Dandliker
Keith W R Watson
Thomas C Drees
Original Assignee
Int Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Therapeutics Inc filed Critical Int Therapeutics Inc
Application granted granted Critical
Publication of ATE147387T1 publication Critical patent/ATE147387T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C23/00—Compounds containing at least one halogen atom bound to a ring other than a six-membered aromatic ring
    • C07C23/18—Polycyclic halogenated hydrocarbons
    • C07C23/20—Polycyclic halogenated hydrocarbons with condensed rings none of which is aromatic
    • C07C23/38—Polycyclic halogenated hydrocarbons with condensed rings none of which is aromatic with three condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT87307490T 1986-08-25 1987-08-25 Perfluoro-hexamethyltetramin und synthetische phopholipide, verwendbar als synthetisches blut ATE147387T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89990386A 1986-08-25 1986-08-25

Publications (1)

Publication Number Publication Date
ATE147387T1 true ATE147387T1 (de) 1997-01-15

Family

ID=25411712

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87307490T ATE147387T1 (de) 1986-08-25 1987-08-25 Perfluoro-hexamethyltetramin und synthetische phopholipide, verwendbar als synthetisches blut

Country Status (4)

Country Link
EP (1) EP0261802B1 (de)
JP (1) JP2589702B2 (de)
AT (1) ATE147387T1 (de)
DE (1) DE3751994D1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931472A (en) * 1985-09-17 1990-06-05 Biomed Technology, Inc. Fluorinated triethylenediamine as an oxygen transport agent
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4402984A (en) * 1980-07-03 1983-09-06 Sun Tech, Inc. Preparation of 1-hydropentadecafluoroadamantane and perfluoroadamantane

Also Published As

Publication number Publication date
JP2589702B2 (ja) 1997-03-12
EP0261802A2 (de) 1988-03-30
EP0261802A3 (de) 1989-11-02
JPS6372633A (ja) 1988-04-02
EP0261802B1 (de) 1997-01-08
DE3751994D1 (de) 1997-02-20

Similar Documents

Publication Publication Date Title
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
ES2087056T3 (es) 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6.
DE3869444D1 (de) D-prostaglandine und ihre anwendung in tranquilizern und hypnotikum.
DK0751959T3 (da) Modificerede polypeptider med forøget biologisk aktivitet
ATE73332T1 (de) Neuartige verwendung von taurolin.
DE69016348D1 (de) Leukozyten und Hämoglobin im Blut.
DE3687362D1 (de) Mischungen von fluorenthaltendem polymer, deren herstellung und anwendung.
DE3789761D1 (de) Reibungsmaterialien und Herstellung derselben.
DE3788584D1 (de) Sulfonylharnstoff-Verbindungen, ihre Herstellung und Verwendung als Herbizide.
DE68915715D1 (de) Membran-Blutoxygenator.
FR2606631B1 (fr) Lit medical ou table medicale
DE3788840D1 (de) Wasserabsorbierende Zusammensetzung mit verlängerter Lagerfähigkeit und welche die Faserbildung erleichtert.
DE3751190D1 (de) Sauerstoffkonzentrationsfühler.
DE3784471D1 (de) Bestimmung und kontrolle von sulfatreduzierenden bakterien.
DE58902290D1 (de) Sauerstoffabsorptionsmittel und verwendung desselben.
NO871053D0 (no) Anvendelse av substituerte n-triklormetyltiodikarboksimider i kombinasjon med n,n[-substituerte bis-(2,4-diamino-s-triazin-6-yl)-oligosulfider i vulkaniserbare kautsjukblandinger og slike kautsjukblandinger.
DE68921447D1 (de) Katalytische Herstellung von linearen Polyethylenpolyaminen.
ATE147387T1 (de) Perfluoro-hexamethyltetramin und synthetische phopholipide, verwendbar als synthetisches blut
EP0270841A3 (de) 2-Methyl-3-(p-methyl-phenyl)-propionitril, dessen Herstellung und Verwendung als Riechstoff
SE8502865D0 (sv) Naphtoxazine, ihre herstellung und verwendung
DE3675069D1 (de) Carboxanilide.
ATE88328T1 (de) Verwendung von efomycinen als leistungsfoerderer bei tieren, efomycine und ihre herstellung.
DE3872981D1 (de) Phenylthioharnstoffe, -isothioharnstoffe und -carbodiimide, ihre herstellung und verwendung bei der kontrolle von schaedlingen.
ATE66218T1 (de) 5-heterocyclisch substituierte-3h-1,2,4-triazol-3-thione und ihre verwendung als antidepressiva.
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.